Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) Non Operating Income (2017 - 2023)

Historic Non Operating Income for Denali Therapeutics (DNLI) over the last 7 years, with Q4 2023 value amounting to $13.1 million.

  • Denali Therapeutics' Non Operating Income rose 9713.21% to $13.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $51.5 million, marking a year-over-year increase of 24861.92%. This contributed to the annual value of $51.5 million for FY2023, which is 24861.92% up from last year.
  • According to the latest figures from Q4 2023, Denali Therapeutics' Non Operating Income is $13.1 million, which was up 9713.21% from $14.4 million recorded in Q3 2023.
  • Denali Therapeutics' 5-year Non Operating Income high stood at $14.4 million for Q3 2023, and its period low was $1.0 million during Q3 2021.
  • Moreover, its 5-year median value for Non Operating Income was $3.3 million (2019), whereas its average is $4.8 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first tumbled by 6158.36% in 2021, then surged by 76338.03% in 2023.
  • Quarter analysis of 5 years shows Denali Therapeutics' Non Operating Income stood at $3.8 million in 2019, then plummeted by 57.2% to $1.6 million in 2020, then dropped by 21.17% to $1.3 million in 2021, then soared by 418.29% to $6.7 million in 2022, then soared by 97.13% to $13.1 million in 2023.
  • Its Non Operating Income was $13.1 million in Q4 2023, compared to $14.4 million in Q3 2023 and $12.9 million in Q2 2023.